Evidence map›Paper›PMID 42796657›Full record

ReviewPathogens (Basel, Switzerland)2026

Prion-like Protein TDP-43: Mechanisms, Diagnosis, and Therapeutic Prospects.

Mika Inada Shimamura, Katsuya Satoh

Abstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mika Inada ShimamuraDepartment of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.ORCID 0000-0002-3830-2173
Katsuya SatohDepartment of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.ORCID 0000-0001-8007-8710

Funding

Japan Agency for Medical Research and Development JP26dk0207077JSPS Program for Forming Japan's Peak Research Universities JPJS00420240024.
6 · The paper itself

Abstract

TDP-43 proteinopathies, encompassing amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), and limbic-predominant age-related TDP-43 encephalopathy (LATE), represent a heterogeneous spectrum of devastating neurodegenerative disorders. For decades, the diverse clinical presentations of these diseases have complicated antemortem diagnosis and hindered the development of disease-modifying therapies. However, recent breakthroughs in basic science are beginning to address these clinical barriers, although substantial hurdles to practical clinical application remain. Structural elucidation via cryo-electron microscopy (Cryo-EM) has shattered the single-protein amyloid dogma by revealing that TDP-43 can form hetero-amyloid filaments with ANXA11, thereby providing a molecular basis for pathological strain diversity. Concurrently, the pathogenic focus has shifted toward nuclear loss of function, which triggers a systemic "RNA crisis" characterized by aberrant alternative polyadenylation (APA) and cryptic exon inclusion (e.g.,

Indexed as

DNA-Binding ProteinsPrionsTDP-43 ProteinopathiesAnimalsHumansDNA-Binding ProteinsPrionsTARDBP protein, humanamyotrophic lateral sclerosis (ALS)cryo-electron microscopy (Cryo-EM)frontotemporal lobar degeneration (FTLD)precision medicineprion-like propagationseed amplification assay (SAA)TDP-43

Identifiers

PMID42796657
PMCPMC13610474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.